98 filings
Page 2 of 5
8-K
p8qr cmpwpru
10 Oct 23
Shuttle Pharma to Participate in the Lytham Partners Fall 2023 Investor Conference
9:00am
8-K
2f4hm8sqvb
5 Oct 23
Entry into a Material Definitive Agreement
4:10pm
8-K
75d5l64w
25 Sep 23
Shuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma
9:00am
8-K
v12z4u v0
7 Sep 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
9:20am
424B3
t65jatv3feg p5cd
24 Aug 23
Prospectus supplement
2:00pm
8-K
4o8i964mlk j5avqjip
15 Aug 23
Shuttle Pharmaceuticals Provides Second Quarter 2023 Corporate Update
9:00am
8-K
iwqqbgi8a az
3 Aug 23
Shuttle Pharmaceuticals Completes Manufacturing of Active Pharmaceutical Ingredient (API) for Use in Clinical Trial
9:00am
DEF 14C
bnyhy
16 Jun 23
Information statement
6:30am
PRE 14C
avc5s4
5 Jun 23
Preliminary information
4:29pm
8-K
rdh4ep7 5suvoqsmhe
5 Jun 23
Entry into a Material Definitive Agreement
8:10am
8-K
mgpxy
26 May 23
Shuttle Pharmaceuticals Provides First Quarter 2023 Corporate Update
9:00am
8-K
vx98b qh83
17 May 23
Shuttle Pharmaceuticals to Participate in the Lytham Partners Spring 2023 Investor Conference
9:00am
NT 10-Q
s4c5xktao 37d1j35b4q
15 May 23
Notice of late quarterly filing
5:26pm
8-K
2pjqvss7i9dpv
11 May 23
Entry into a Material Definitive Agreement
8:12am
8-K
4xqcwm x7
3 May 23
Departure of Directors or Certain Officers
4:10pm
8-K
w22nrnrpjhftk77uu
22 Mar 23
Entry into a Material Definitive Agreement
9:00am
10-K
efsheldfdwhrefe
15 Mar 23
Annual report
9:00am
8-K
edkdrgppohx3lm
9 Mar 23
Shuttle Pharmaceuticals Engages UI Pharmaceuticals for Formulation and Clinical Batch Manufacture of Ropidoxuridine for Brain Tumor Clinical Trial
9:00am